Hans Georg Eichler

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers: What can we learn from clinical research?
    Hans Georg Eichler
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Eur J Health Econ 7:129-35. 2006
  2. ncbi request reprint Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?
    Hans Georg Eichler
    Vienna Center for Pharmaceutical Policy, Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Value Health 7:518-28. 2004
  3. ncbi request reprint Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model
    Thomas Sycha
    Department of Neurology, Medical University of Vienna, Währinger Gürtel 18 20 A 1090 Vienna, Austria
    Pain 113:316-22. 2005
  4. ncbi request reprint Effect of information on reported adverse events in a placebo-controlled trial
    Michael Ossege
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Drug Saf 28:81-7. 2005
  5. pmc A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects
    Thomas Sycha
    Department of Clinical Pharmacology, Institute of Medical Physics, Vienna University School of Medicine, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Br J Clin Pharmacol 56:165-72. 2003
  6. ncbi request reprint Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans
    Ursula Hollenstein
    Department of Clinical Pharmacology, Internal Medicine I, Division of Infectious Diseases, Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Pharmacol Ther 71:368-74. 2002
  7. ncbi request reprint Influence of tiapride on platelet counts in healthy volunteers and patients with movement disorders
    Nicole Kotzailias
    Department of Clinical Pharmacology TARGET, Vienna University, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Prog Neuropsychopharmacol Biol Psychiatry 27:595-9. 2003
  8. pmc Target site concentrations of ciprofloxacin after single intravenous and oral doses
    Martin Brunner
    Department of Clinical Pharmacology, University of Vienna Medical School, Austria
    Antimicrob Agents Chemother 46:3724-30. 2002
  9. ncbi request reprint Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans
    Bernd Jilma
    Department of Clinical Pharmacology, Vienna University, Vienna, Austria
    Clin Pharmacol Ther 72:403-10. 2002
  10. ncbi request reprint A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations
    Christian Joukhadar
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, University of Vienna Medical School, Allgemeines Krankenhaus, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Eur J Clin Pharmacol 59:631-6. 2003

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers: What can we learn from clinical research?
    Hans Georg Eichler
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Eur J Health Econ 7:129-35. 2006
    ....
  2. ncbi request reprint Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?
    Hans Georg Eichler
    Vienna Center for Pharmaceutical Policy, Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Value Health 7:518-28. 2004
    ..It is expected that thresholds for CE ratios may be established for the acceptance of reimbursement or formulary listing...
  3. ncbi request reprint Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model
    Thomas Sycha
    Department of Neurology, Medical University of Vienna, Währinger Gürtel 18 20 A 1090 Vienna, Austria
    Pain 113:316-22. 2005
    ..We confirm that the effect of single oral dose of rofecoxib plateaus at 50 mg...
  4. ncbi request reprint Effect of information on reported adverse events in a placebo-controlled trial
    Michael Ossege
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Drug Saf 28:81-7. 2005
    ..We hypothesised that information about the likelihood of receiving placebo might influence the perception of adverse effects in volunteers participating in a clinical trial...
  5. pmc A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects
    Thomas Sycha
    Department of Clinical Pharmacology, Institute of Medical Physics, Vienna University School of Medicine, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Br J Clin Pharmacol 56:165-72. 2003
    ..We evaluated an experimental pain model for NSAIDs, that included an inflammatory component to mimic clinical inflammatory pain conditions...
  6. ncbi request reprint Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans
    Ursula Hollenstein
    Department of Clinical Pharmacology, Internal Medicine I, Division of Infectious Diseases, Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Pharmacol Ther 71:368-74. 2002
    ..To evaluate the applicability of a well-established model of tissue factor-dependent coagulation for defining anticoagulant potency, we investigated the effects of acenocoumarol in experimental human endotoxemia...
  7. ncbi request reprint Influence of tiapride on platelet counts in healthy volunteers and patients with movement disorders
    Nicole Kotzailias
    Department of Clinical Pharmacology TARGET, Vienna University, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Prog Neuropsychopharmacol Biol Psychiatry 27:595-9. 2003
    ..The selective D2 antagonist tiapride is administered in various movement disorders. Furthermore, there are indications that tiapride increases platelet counts...
  8. pmc Target site concentrations of ciprofloxacin after single intravenous and oral doses
    Martin Brunner
    Department of Clinical Pharmacology, University of Vienna Medical School, Austria
    Antimicrob Agents Chemother 46:3724-30. 2002
    ..These differences, however, are not related to a difference in target site pharmacodynamics...
  9. ncbi request reprint Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans
    Bernd Jilma
    Department of Clinical Pharmacology, Vienna University, Vienna, Austria
    Clin Pharmacol Ther 72:403-10. 2002
    ..This lethal animal model suggested that tissue factor also influences inflammatory cascades...
  10. ncbi request reprint A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations
    Christian Joukhadar
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, University of Vienna Medical School, Allgemeines Krankenhaus, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Eur J Clin Pharmacol 59:631-6. 2003
    ..Therefore, a single-dose, replicate study design was used to evaluate bioequivalence of two desmopressin nasal sprays...
  11. ncbi request reprint Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension
    Gabriele Fuchsjager-Mayrl
    Departments of Clinical Pharmacology and Ophthalmology, and the Institute of Medical Physics, University of Vienna, Vienna, Austria
    Invest Ophthalmol Vis Sci 45:834-9. 2004
    ..In the present study, the baseline characteristics were examined in a study population participating in a clinical trial in which the ocular hemodynamic effects of timolol and dorzolamide were compared...
  12. pmc Drug reimbursement: indicators of inappropriate resource allocation
    Bernard Begaud
    Department de Pharmacologie, Universite Victor Segalen Bordeaux 2, Hopital Pellegrin, F33076 Bordeaux Cedex, France
    Br J Clin Pharmacol 54:528-34. 2002
    ....
  13. ncbi request reprint Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications
    Olga Geling
    Department of Public Health Sciences and Epidemiology, John A Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA
    J Clin Oncol 23:1289-94. 2005
    ..The purpose of this study was to provide estimates of clinical efficacy and drug acquisition cost associated with administering 5-HT(3) antagonists beyond 24 hours, as monotherapy or as added to dexamethasone...
  14. ncbi request reprint Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans
    la Peña Amparo de
    Department of Pharmaceutics, University of Florida, Gainesville 32610, USA
    J Clin Pharmacol 42:403-11. 2002
    ..The data of the present study indicate that time above MIC values at the target site can be substantially prolonged if an antibiotic is administered as a sustained-release product...
  15. ncbi request reprint How drug prices are set: an example from the perspective of a social security association
    Hans Georg Eichler
    Clin Pharmacol Ther 72:101-3. 2002
  16. doi request reprint Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
    Hans Georg Eichler
    European Medicines Agency, Canary Wharf, London, UK
    Nat Rev Drug Discov 7:818-26. 2008
    ....